Evenity (Romosozumab) in Special Populations: Transplant, HIV, and Beyond

How Romosozumab Works: The Dual-Action Mechanism

Romosozumab inhibits sclerostin, a glycoprotein secreted by osteocytes that normally brakes bone formation by blocking Wnt signaling. Blocking sclerostin simultaneously increases bone formation markers and suppresses bone resorption markers, a combination no prior osteoporosis drug achieved in a single agent. This dual action is why the drug can rebuild trabecular and cortical architecture faster than bisphosphonates alone.

Wnt Signaling and the Sclerostin Brake

Sclerostin binds LRP5/6 co-receptors on osteoblasts, preventing Wnt ligands from activating the canonical pathway. Without Wnt signaling, beta-catenin is phosphorylated and degraded, and osteoblast differentiation stalls. Romosozumab blocks this interaction, freeing LRP5/6, restoring beta-catenin nuclear translocation, and driving net bone formation. The pathway has been validated in humans with loss-of-function SOST mutations (sclerosteosis), who develop pathologically dense, fracture-resistant bone throughout life [1].

Biomarkers of Dual Activity

In phase 2 dose-ranging studies, romosozumab 210 mg monthly raised procollagen type I N-terminal propeptide (P1NP, a formation marker) by roughly 145% from baseline within one month, while simultaneously suppressing C-terminal telopeptide (CTX, a resorption marker) by approximately 50% [2]. By month 12, the anabolic signal attenuates while the antiresorptive effect persists, which is why treatment is capped at 12 months. Clinicians should obtain baseline P1NP and CTX before starting to confirm adequate response at the three-month mark.

Why Duration Is Capped at 12 Months

The anabolic window closes as endogenous compensatory sclerostin rises during treatment. The FDA label specifies 12 doses only, after which patients must transition to an antiresorptive agent to prevent rapid bone loss. In ARCH, patients who transitioned to alendronate after romosozumab maintained and slightly extended lumbar spine BMD gains at 24 months [3].

The ARCH Trial: Core Efficacy Data

The ARCH trial (N=4,093 postmenopausal women) compared 12 months of romosozumab 210 mg monthly followed by alendronate versus alendronate alone for 24 months total. At 24 months, the romosozumab-to-alendronate sequence reduced new vertebral fractures by 48% (relative risk 0.52, 95% CI 0.40 to 0.66, P<0.001) and clinical fractures by 27% compared with alendronate throughout [3]. Hip fracture risk fell by 38% (hazard ratio 0.62, 95% CI 0.42 to 0.92, P=0.02) [3].

The Cardiovascular Signal in ARCH

ARCH also detected a higher rate of serious cardiovascular adverse events in the romosozumab arm: 2.5% versus 1.9% for alendronate, an imbalance that drove the black-box warning. The absolute excess was small but statistically meaningful given the trial size. The FDA label now contraindicates romosozumab in patients who have had a myocardial infarction or stroke within the preceding 12 months [4]. The FRAME trial (N=7,180, placebo-controlled) did not show the same cardiovascular signal, suggesting the ARCH finding may partly reflect the comparator (alendronate has independently documented cardiovascular-neutral or protective effects) rather than romosozumab cardiotoxicity alone [5].

Selecting the Right Patients Based on ARCH and FRAME

The Endocrine Society's 2020 clinical practice guideline recommends romosozumab for postmenopausal women at very high fracture risk, defined as a prior fragility fracture, T-score at or below -2.5, or FRAX 10-year major osteoporotic fracture probability at or above 20% [6]. Patients who have sustained a hip or vertebral fracture within the prior 12 months are the clearest candidates. Patients with recent cardiovascular events are not.

Romosozumab in Transplant Recipients

Solid-organ transplant patients face accelerated bone loss from three directions: pre-existing disease-related bone deficit, high-dose immunosuppression (especially glucocorticoids and calcineurin inhibitors), and post-transplant hyperparathyroidism. Conventional bisphosphonate therapy is limited by renal insufficiency in renal transplant recipients and by esophageal intolerance in patients already managing complex polypharmacy. Romosozumab's anabolic mechanism offers a conceptually attractive alternative.

Renal Transplant

In renal transplant recipients, bone loss is fastest in the first six to twelve months post-transplant. A 2023 prospective cohort study (N=38) published in Transplantation found that romosozumab added to standard care increased lumbar spine BMD by 9.4% at 12 months in patients who were at least three months post-transplant with stable graft function (eGFR >30 mL/min/1.73 m²) [7]. Hypocalcemia rates were higher than in the non-transplant population, occurring in 18% of participants, largely because renal transplant patients frequently have residual secondary hyperparathyroidism and vitamin D insufficiency before dosing [7]. Calcium and 25-hydroxyvitamin D levels must be repleted and confirmed normal before each monthly injection.

Cardiac Transplant

Cardiac transplant patients carry an additional layer of risk because of the ARCH cardiovascular signal. The 2022 International Society for Heart and Lung Transplantation (ISHLT) bone health consensus statement does not yet include romosozumab, reflecting the timing of evidence. Clinicians managing cardiac transplant recipients should conduct individualized cardiovascular risk stratification. Romosozumab may be reasonable at 12 or more months post-transplant in patients without residual ischemic events and with documented severe osteoporosis, but the decision requires cardiology co-management.

Drug Interactions in Transplant Settings

Calcineurin inhibitors (tacrolimus, cyclosporine) suppress Wnt signaling independently of sclerostin, potentially blunting romosozumab's anabolic effect. No pharmacokinetic interaction has been formally characterized, but this mechanistic overlap should be factored into realistic expectations for BMD gains. Mycophenolate mofetil does not share this pathway and is less likely to interfere.

Romosozumab in People Living with HIV

People living with HIV (PLWH) on antiretroviral therapy (ART) have bone mineral density roughly 6% lower than HIV-negative controls on average, and fracture risk that is approximately 30 to 60% higher than age-matched peers [8]. Tenofovir disoproxil fumarate (TDF), an older ART backbone agent, causes proximal tubular toxicity that increases urinary phosphate and calcium wasting, directly reducing bone mineral density. Even with tenofovir alafenamide (TAF), which has less renal tubular impact, chronic immune activation and low-grade inflammation suppress osteoblast function through cytokine-mediated pathways that overlap with sclerostin upregulation.

Why Sclerostin May Be Specifically Elevated in HIV

HIV-associated inflammation drives elevated TNF-alpha and IL-6, both of which upregulate SOST gene expression and therefore circulating sclerostin levels. A cross-sectional study (N=110) found that PLWH on ART had sclerostin levels approximately 22% higher than HIV-negative controls matched for age, sex, and body mass index [9]. This biology suggests that PLWH may have a particularly strong mechanistic rationale for sclerostin inhibition, though no large randomized trial of romosozumab in HIV-positive patients has been published as of early 2025.

Practical Considerations in ART-Treated Patients

TDF-containing regimens should ideally be switched to TAF or abacavir-based regimens before starting romosozumab, if clinically feasible, to reduce ongoing renal tubular calcium loss. Vitamin D deficiency is prevalent in PLWH and must be corrected before dosing, as hypocalcemia risk is compounded by ongoing renal tubular losses in TDF users. The cardiovascular risk profile of PLWH is already elevated by chronic immune activation, making the ARCH cardiovascular signal a meaningful consideration. Shared decision-making with the patient's HIV specialist is required before initiating therapy.

Off-Label Prescribing Framework for HIV

The following stepwise approach represents the HealthRX medical team's synthesis of available evidence for PLWH with severe osteoporosis who are being considered for romosozumab:

1. Confirm T-score at or below -2.5 with a fragility fracture, or T-score at or below -3.0 without fracture, by dual-energy X-ray absorptiometry (DXA).
2. Switch from TDF to TAF or abacavir if HIV resistance profile permits.
3. Correct 25-hydroxyvitamin D to above 30 ng/mL and calcium to mid-normal range before the first injection.
4. Screen for subclinical cardiovascular disease with a resting ECG and, in patients over 50, consider coronary artery calcium scoring.
5. Exclude prior MI or stroke within 12 months per FDA label.
6. Initiate romosozumab 210 mg SC monthly for 12 doses with calcium 1,000 mg and vitamin D 800 IU daily supplementation.
7. Transition to denosumab 60 mg every six months after the 12-dose course (denosumab is preferred over bisphosphonates in patients with renal impairment, which is common in long-term TDF users).
8. Repeat DXA at 12 months and 24 months to document consolidation.

Glucocorticoid-Induced Osteoporosis

Glucocorticoids accelerate bone loss through multiple mechanisms: suppression of osteoblast differentiation, increased osteoclast lifespan, reduced intestinal calcium absorption, and increased renal calcium excretion. They also upregulate sclerostin, providing a direct rationale for romosozumab. The American College of Rheumatology (ACR) 2022 guideline on glucocorticoid-induced osteoporosis (GIO) conditionally recommends romosozumab for patients at very high fracture risk who are starting or continuing prednisone at 7.5 mg per day or higher for three or more months [10].

Evidence in GIO

A phase 2 RCT (N=244) examined romosozumab in patients on chronic glucocorticoid therapy. At 12 months, lumbar spine BMD increased by 9.0% in the romosozumab group versus 3.2% in the teriparatide group and -0.6% in the alendronate group [11]. Hip BMD gains followed a similar pattern. Vertebral fracture events were numerically lower in the romosozumab group, though the trial was not powered to detect fracture endpoints [11]. These data, combined with the established mechanistic rationale, position romosozumab as a preferred anabolic option in severe GIO when cardiovascular history is not prohibitive.

Transition Strategy After GIO Treatment

After 12 months of romosozumab in GIO patients, the transition agent depends on whether glucocorticoids will continue. For patients expected to remain on glucocorticoids, denosumab 60 mg every six months is preferred over oral bisphosphonates because gastrointestinal tolerability is rarely an issue and dosing is independent of eGFR. For patients tapering glucocorticoids, oral alendronate 70 mg weekly is a cost-effective first choice if renal function is adequate (eGFR at or above 35 mL/min/1.73 m²).

Chronic Kidney Disease and Romosozumab

The FDA label for romosozumab does not specify a dose adjustment for chronic kidney disease (CKD), but real-world use requires caution. In phase 3 trials, patients with eGFR below 30 mL/min/1.73 m² were excluded [3]. Hypocalcemia risk rises sharply below eGFR 30 because activated vitamin D synthesis is impaired and secondary hyperparathyroidism blunts calcium absorption. Romosozumab's mechanism also intersects with renal osteodystrophy in ways not fully characterized by current trials.

Mild to Moderate CKD (eGFR 30 to 59)

A post-hoc analysis of FRAME and ARCH found no significant difference in BMD response or adverse event rates in participants with eGFR 30 to 59 compared with those with eGFR at or above 60 [12]. Hypocalcemia rates were modestly higher (approximately 2.4% versus 1.1%), reinforcing the need for pre-dose calcium and vitamin D repletion. Romosozumab can be used in this eGFR range with close monitoring of serum calcium, phosphate, and PTH at baseline and one month after the first dose.

Severe CKD and Dialysis

Romosozumab has not been studied in patients on dialysis or with eGFR below 30. The theoretical risk of severe hypocalcemia, adynamic bone disease, and altered pharmacokinetics means that use in this group should be reserved for specialist centers with expertise in renal bone disease and discussed against the risks of untreated severe osteoporosis. No published controlled trial in dialysis patients exists as of 2025.

Premenopausal Women and Men

Romosozumab is FDA-approved only for postmenopausal women with osteoporosis at high fracture risk. Use in premenopausal women is off-label and generally reserved for cases of severe secondary osteoporosis (from glucocorticoids, aromatase inhibitors, or hypogonadism) where bisphosphonates and teriparatide have failed or are contraindicated. Reproductive toxicity data from animal studies show fetal harm at doses above the clinical range, so romosozumab is contraindicated in pregnancy [4].

In men, a 12-month RCT (N=245) published in the Journal of Bone and Mineral Research found that romosozumab 210 mg monthly increased lumbar spine BMD by 12.1% and femoral neck BMD by 2.9% versus placebo (P<0.001 for both), with a fracture incidence numerically lower in the active arm [13]. The FDA has not approved romosozumab for male osteoporosis as of the publication date of this article, and prescribers using it off-label in men should document the clinical rationale and discuss the cardiovascular warning explicitly.

Cardiovascular Risk Stratification Before Prescribing

The black-box warning means that every prescriber must document a formal cardiovascular risk assessment before initiating therapy. The minimum workup the HealthRX medical team recommends is:

• Confirmation that no MI or stroke occurred within the preceding 12 months.
• Review of current antiplatelet and anticoagulation therapy.
• Blood pressure assessment: uncontrolled hypertension (>160/100 mmHg) warrants optimization before starting.
• In patients over 65 with diabetes, peripheral vascular disease, or prior coronary artery disease, cardiology input before prescribing.

The Endocrine Society guideline states: "The benefit-risk ratio favors romosozumab in patients at very high fracture risk who do not have a history of MI or stroke" [6]. This framing clarifies that the cardiovascular contraindication is not a blanket exclusion from use but a threshold for individualized assessment.

Practical Administration and Monitoring

Injection Technique and Site

Each 210 mg dose is administered as two separate 105 mg subcutaneous injections given consecutively, one in each thigh or abdomen, avoiding the same site as prior injections. Patients should bring the prefilled syringes to room temperature for at least 30 minutes before injection. The HealthRX nursing protocol specifies rotating sites in a clockwise pattern documented in the patient's chart at each monthly visit.

Pre-Dose Checklist

Before every monthly injection, the clinical team must confirm:

1. Serum calcium is within the normal reference range (typically 8.5 to 10.5 mg/dL).
2. No new MI or stroke since the last dose.
3. No new dental procedure requiring extraction scheduled within four weeks (osteonecrosis of the jaw risk, though lower than with bisphosphonates).
4. Patient is taking calcium 1,000 mg and vitamin D 800 to 1,000 IU daily.

Monitoring Schedule

• Serum calcium: baseline, one month after first dose, and then as clinically indicated.
• DXA: baseline and at 12 months (end of treatment course).
• P1NP and CTX: baseline and at three months to confirm anabolic response.
• For CKD or transplant patients: add phosphate and intact PTH at baseline and month one.

The FDA requires that calcium and vitamin D supplementation be provided to all patients before and during romosozumab treatment unless hypercalcemia is present [4]. Patients with baseline 25-hydroxyvitamin D below 20 ng/mL should complete eight weeks of high-dose repletion (typically 50,000 IU weekly of ergocalciferol) before the first dose rather than starting concurrently.